Stay updated with breaking news from Mjamesf Howard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UCB announces U.S. FDA approval of ZILBRYSQ[®] for the treatment of adults with generalized myasthenia gravis FDA approval of ZILBRYSQ® has been granted...
Zilucoplan is the first once-daily, subcutaneous, self-administered, targeted C5 complement inhibitor for adults with gMG who are AChR antibody positive.
The approval marks the first and only once-daily target therapy for generalized myasthenia gravis for self-administration in this patient population.
FDA approval of ZILBRYSQ® has been granted for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody-positive1ZILBRYSQ is the first...
Future myasthenia gravis therapies have different mechanisms of action than current treatments, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.